Clinical Management Guidelines for MSH6 Variants

This guide outlines clinical management guidelines for patients with a pathogenic or likely pathogenic variant in the MSH6 gene, which is associated with Lynch syndrome. The guidelines are primarily based on recommendations from the National Comprehensive Cancer Network (NCCN) and detail various cancer risks, including colorectal, endometrial, gastric, and ovarian cancers. It emphasizes the importance of individualized treatment plans and the need for discussions between patients and healthcare providers regarding risk management options. The document includes specific recommendations for cancer screening and surgical considerations, such as the age to start screenings and the frequency of these procedures. Additionally, it addresses the implications for family members and the potential for passing on genetic risks. The guidelines also highlight the importance of genetic counseling and the need for ongoing communication with healthcare providers as the field of cancer genetics evolves.